Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Astria Therapeutics，Inc.（納斯達克：ATXS）是一家專注於開發過敏性和免疫性疾病的改變人生療法的生物製藥公司，今天宣佈將於2024年9月26日在荷蘭阿姆斯特丹舉行的歐洲皮膚病學和性病學學會（EADV）大會上展示初步的Navenibart ALPHA-STAR數據。
Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled "ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes." The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.
Raffi Tachdjian博士，MPH，畢業於加利福尼亞大學洛杉磯分校（UCLA）大衛·格芬醫學院（David Geffen School of Medicine），是醫學和兒科過敏和臨床免疫學部的副臨床教授，將在週四2024年9月26日下午4點20分CESt在電子海報展示區六上展示題爲「ALPHA-STAR的海報」，STARS-0215在遺傳性血管性水腫患者中單劑和多劑臨床試驗的初步安全性和療效結果。”
譯文內容由第三人軟體翻譯。
